Description: ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral and inflammatory disease.
Home Page: www.abivax.com
5, rue de la Baume
Paris,
75008
France
Phone:
33 1 53 83 08 41
Officers
| Name | Title |
|---|---|
| Prof. Hartmut J. Ehrlich | Chief Exec. Officer |
| Dr. Philippe Pouletty M.D., Ph.D. | Founder & Director |
| Mr. Didier Blondel | EVP, CFO & Board Sec. |
| Ms. Raquel Lizarraga | Investor Relations Mang. |
| Ms. Regina Jehle | VP Communications |
| Anne Pascard | HR Mang. |
| Mr. Pierre Courteille M.B.A. | Chief Commercial Officer & VP of Bus. Devel. |
| Dr. Alexandra Pearce | VP of Regulatory Affairs, Quality & Pharmaco-Vigilance |
| Mr. Paul Gineste | VP Clinical Operations |
| Mr. Alain Chevallier | Sr. Advisor |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 27.5659 |
| Price-to-Sales TTM: | 20.6517 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |